

## Použitá literatura

- ACOG Practice Bulletin No. 206 Summary: use of hormonal contraception in women with coexisting medical conditions. *Obstet Gynecol.* 2019;133(2):396-399.
- Ahrendt HJ, Makalova D, Parke S et al. Bleeding Pattern and Cycle Control With an Estradiol-Based Oral Contraceptive: A Seven-Cycle, Randomized Comparative Trial of Estradiol Valerate/Dienogest and Ethinyl Estradiol/Levonorgestrel. *Contraception.* 2009, 80:436–44.
- Bauer KA. Hypercoagulable states In Hoffman R, Benz EJ, Shattil SJ et al. Hematology: Basic Principles and Practice, New York, Churchill Livingstone 2008, s.1165-70, ISBN 0443067155, s.2560.
- Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics - 2018 update. *Circulation.* 2018;137(12):e67-e492.
- Bosch van den MA, Kemmeren JM, Tanis BC et al. The RATIO study: oral contraceptives and the risk of peripheral arterial disease in young women. *J Thromb Haemost.* 2003; 1 (3): 439-44.
- British Thoracic Society Standards of Care Committee Pulmonary Embolism Guideline Development Group. British Thoracic Society guidelines for the management of suspected acute pulmonary embolism. *Thorax.* 2003;58(6):470-83.
- Coelingh Bennink HJ, Holinka CF, Diczfalusy E. Estetrol Review: Profile and Potential Clinical Applications. *Climacteric.* 2008, 11 Suppl 1:47–58.
- Curtis KM, Tepper NK, Jatlaoui TC, et al. US medical eligibility criteria for contraceptive use, 2016. *MMWR Recomm Rep.* 2016;65(3):1-103.
- Davis MB, Arendt K, Bello NA, et al. Team-based care of women with cardiovascular disease from pre-conception through pregnancy and postpartum. *J Am Coll Cardiol.* 2021;77(14):1763-1777.
- De Bastos M, Stegeman BH, Rosendaal FR, Van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, Dekkers OM. Combined oral contraceptives: venous thrombosis. *Cochrane Database Syst Rev.* 2014 Mar 3;(3):CD010813.
- Dinger JC, Heinemann LA, Kühl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. *Contraception* 2007;75(5):344-54.
- Dou W, Huang Y, Liu X, Huang C, Huang J, Xu B, Yang L, Liu Y, Lei X, Li X, Huang J, Lin J, Liu D, Zhang P, Shao J, Liu C, Zhang H. Associations of Oral Contraceptive Use With Cardiovascular

Disease and All-Cause Death: Evidence From the UK Biobank Cohort Study. *J Am Heart Assoc.* 2023 Aug 15;12(16):e030105. doi: 10.1161/JAHA.123.030105. Epub 2023 Aug 10. PMID: 37581386; PMCID: PMC10492942.

Douxflis J, Klipping C, Duijkers I et al. Evaluation of the Effect of a New Oral Contraceptive Containing Estetrol and Drospirenone on Hemostasis Parameters. *Contraception.* 2020, 102:396–402.

Girolami A, Scandellari R, Tezza F et al. Arterial thrombosis in young women after ovarian stimulation: case report and review of the literature. *J Thromb Thrombol.* 2007; 24 (2): 169-7.

Gruhn JG, Kazer RR. *Hormonal Regulation of the Menstrual Cycle: The Evolution of Concepts.* Springer Science and Business Media, 2013. pp. 185. ISBN 978-1-4899-3496-3.

Haynes M., Sinha D., Russell K., Collinge M., Fulton D., Morales-Ruiz M. et al.. Membrane Estrogen Receptor Engagement Activates Endothelial Nitric Oxide Synthase Via the Pi3-kinase-akt Pathway In Human Endothelial Cells. *Circulation Research* 2000;87(8):677-682.

Heikinheimo O, Toffol E, Partonen T, But A, Latvala A, Haukka J. Systemic hormonal contraception and risk of venous thromboembolism. *Acta Obstetrica et Gynecologica Scandinavica.* 2022;101(8):846–55.

Hylckama Vlieg van A, Helmerhorst FM, Vandenbroucke JP et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. *BMJ.* 2009; 339: b2921.

Chuang C., Velott D., & Weisman C.. Exploring knowledge and attitudes related to pregnancy and preconception health in women with chronic medical conditions. *Maternal and Child Health Journal* 2009;14(5):713-719.

Jungers P, Dougados M, Pélissier C et al. Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus. *Arthritis Rheum.* 1982;25(6):618.

Keenan L, Kerr T, Duane M, Van Gundy K. Systematic Review of Hormonal Contraception and Risk of Venous Thrombosis. *Linacre Q.* 2018 Nov;85(4):470-477. doi: 10.1177/0024363918816683. Epub 2019 Jan 3. PMID: 32431379; PMCID: PMC6322116.

Khader YS, Rice J, John L, Abueita O. Oral contraceptives use and the risk of myocardial infarction: a meta-analysis. *Contraception.* 2003; 68 (1): 11-7.

Lidegaard Ø, Milsom I, Geirsson RT et al. Hormonal contraception and venous thromboembolism. *Acta Obstet Gynecol Scand.* 2012;91(7):769-78.

Lindley KJ, Bairey Merz CN, Davis MB, et al. Contraception and reproductive planning for women with cardiovascular disease. *J Am Coll Cardiol.* 2021;77(14):1823-1834.

Liu H. , Yao J. , Wang W. , Zhang D. Association Between Duration Of Oral Contraceptive Use and Risk Of Hypertension: A Meta-analysis. *J Clin Hypertens* 2017;19(10):1032-1041.

Lubianca JN, Faccin CS, Fuchs FD. Oral contraceptives: a risk factor for uncontrolled blood pressure among hypertensive women. *Contraception*. 2003; 67 (1): 19-24.

Mammen EF. Oral contraceptive pills and hormonal replacement therapy and thromboembolic disease. *Hematol Oncol Clin North Am*. 2000; 14 (5): 1045-59.

Meade TW, Haines AP, North WRS et al. Haemostatic, Lipid, and Blood-Pressure Profiles of Women on Oral Contraceptives Containing 50 µg or 30 µg Oestrogen. *Lancet*.1977,948–51.

Mohammed S, Favalaro EJ. Laboratory Testing for Activated Protein C Resistance (APCR). *Methods Mol Biol*. 2017;1646:137-143. doi: 10.1007/978-1-4939-7196-1\_10. PMID: 28804824.

Morimont L, DognéJ-M, Douxfils J. Letter to the Editors-in-Chief in Response to the Article of Abou-Ismaïl, Et Al. Entitled “Estrogen and Thrombosis: A Bench to Bedside Review” (Thrombosis Research 192. 2020, 40–51). *Thromb Res*. 2020, 193:221–3.

Morimont L, Haguet H, Dogné JM, et al. Combined oral contraceptives and venous thromboembolism: review and perspective to mitigate the risk. *Front Endocrinol*. 2021;12:769187.

Nappi RE, Merki-Feld GS, Terreno E, Pellegrinelli A, Viana M. Hormonal contraception in women with migraine: is progestogen-only contraception a better choice? *J Headache Pain*. 2013 Aug 1;14(1):66. doi: 10.1186/1129-2377-14-66. PMID: 24456509; PMCID: PMC3735427.

Peters AA, Buchanan G, Ricciardelli C et al. Androgen Receptor Inhibits Estrogen Receptor-Alpha Activity and Is Prognostic in Breast Cancer. *Cancer Res*. 2009, 69:6131–40.

Pons-Estel GJ, Alarcón GS, Scofield L et al. Understanding the epidemiology and progression of systemic lupus erythematosus. *Semin Arthritis Rheum*. 2010;39(4):257.

Regidor PA. The Clinical Relevance of Progestogens in Hormonal Contraception: Present Status and Future Developments. *Oncotarget*.2018,9:34628–538.

Rosendaal FR, Van Hylckama Vlieg A, Tanis BC et al. Estrogens, progestogens and thrombosis. *J Thromb Haemost*. 2003; 1 (7): 1371-80.

Rosendaal FR. Venous thrombosis: the role of genes, environment, and behavior. *Hematology Am Soc Hematol Educ Program*. 2005; 1-12.

Schürks M, Rist PM, Bigal ME et al. Migraine and cardiovascular disease: systematic review and meta-analysis. *BMJ*. 2009 27;339:b3914

Schwarz E., Postlethwaite D., Hung Y., Lantzman E., Armstrong M., & Horberg M.. Provision of contraceptive services to women with diabetes mellitus. *Journal of General Internal Medicine* 2011;27(2):196-201.

Suthipongse W, Taneepanichskul S. An open-label randomized comparative study of oral contraceptives between medications containing 3 mg drospirenone/30 microg ethinylestradiol and 150 microg levonogestrel/30 microg ethinylestradiol in Thai women. *Contraception*. 2004; 69 (1): 23-6.

Tepper NK, Whiteman MK, Marchbanks PA, James AH, Curtis KM. Progestin-only contraception and thromboembolism. *Contraception* 2016;94(6):678-700.

Tchaikovski S, Tans G, Rosing J. Venous Thrombosis and Oral Contraceptives: Current Status. *Womens Health (Lond)*. 2006, 2:761–72.

Urbanus RT, Siegerink B, Roest M et al. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. *Lancet Neurol*. 2009;8(11):998.

Wessler S, Gitel SN, Wan LS et al. Estrogen-Containing Oral Contraceptives Agents: A Basis for Their Thrombogenicity. *JAMA*.1976,236:2179–82.

Wiegratz I, Kuhl H. Metabolic and Clinical Effects of Progestogens. *Eur J Contracept Reprod Health Care*,2006, 11:153–61.

Wiegratz I, Lee JH, Kutschera E et al. Effect of Four Oral Contraceptives on Hemostatic Parameters. *Contraception*. 2004, 70:97–106.

Yazdany J., Trupin L., Kaiser R., Schmajuk G., Gillis J., Chakravarty E.et al.. Contraceptive counseling and use among women with systemic lupus erythematosus: a gap in health care quality?. *Arthritis Care & Research* 2010:n/a-n/a.

Yildizhan R, Yildizhan B, Adali E et al. Effects of two combined oral contraceptives containing ethinylestradiol 30 mcg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure. *Arch Gynecol Obstet*. 2009; 280 (2): 255-61.